Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
18 hedge funds and large institutions have $107K invested in Titan Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.44% less ownership
Funds ownership: 4.12% → 1.68% (-2.4%)
10% less funds holding
Funds holding: 20 → 18 (-2)
32% less capital invested
Capital invested by funds: $158K → $107K (-$51.2K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$93.6K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.06K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$50.7K |
| 2 |
Renaissance Technologies
New York
|
-$47.8K |
| 3 |
MG
Marex Group
London,
|
-$44.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 5 |
CIA
Cape Investment Advisory
Mcdonough,
Georgia
|
-$4 |
TTNP Hedge Fund Activity: Q3 2025 in Review
18 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2025, worth a combined $107K — down 32% from $158K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TTNP and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was DRW Securities, opening a new position worth an estimated $93.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $50.7K sold.
- 18 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2025, down from 20 in Q2 2025.
- Funds reported $107K of Titan Pharmaceuticals stock for Q3 2025, down 32% quarter-over-quarter.
- 3 funds opened new Titan Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of -2 holders.
- The largest Titan Pharmaceuticals buyer in Q3 2025 was DRW Securities, an estimated $93.6K added.
- The largest Titan Pharmaceuticals seller in Q3 2025 was Citadel Advisors, an estimated $50.7K sold.
Based on aggregated 13F filings for Q3 2025.